These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 11362989

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Oral ganciclovir.
    Schouten JT.
    STEP Perspect; 1995; 7(3):1, 11. PubMed ID: 11362979
    [Abstract] [Full Text] [Related]

  • 3. CMV drug approved.
    Treat Rev; 1995 Nov; (no 20):5. PubMed ID: 11363026
    [Abstract] [Full Text] [Related]

  • 4. Oral ganciclovir approved for CMV.
    Common Factor; 1995 Apr; (no 10):21. PubMed ID: 11362347
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hopeful CMV drug stalled.
    Proj Inf Perspect; 1997 Jul; (22):13. PubMed ID: 11364570
    [Abstract] [Full Text] [Related]

  • 7. Ganciclovir implants: one year later.
    Cadman J.
    GMHC Treat Issues; 1997 Jul; 11(4/5):3-6. PubMed ID: 11364375
    [Abstract] [Full Text] [Related]

  • 8. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Jul; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 9. CMV news.
    Posit Aware; 1996 Jul; 7(1):5-6. PubMed ID: 11363124
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients.
    Monforte V, Román A, Gavaldà J, Bravo C, Gispert P, Pahissa A, Morell F.
    Transplant Proc; 2005 Nov; 37(9):4039-42. PubMed ID: 16386621
    [Abstract] [Full Text] [Related]

  • 12. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T, Opatrny K, Bouda M, Treska V, Jindra P, Svecova M.
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [Abstract] [Full Text] [Related]

  • 13. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM, Subramaniam S.
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Oral ganciclovir approved.
    AIDS Treat News; 1995 Jan 06; (No 214):1. PubMed ID: 11362183
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ganciclovir prophylaxis for CMV disease infrequently associated with viral resistance.
    AIDS Patient Care; 1995 Dec 06; 9(6):308. PubMed ID: 11361450
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.
    Paya CV, Wilson JA, Espy MJ, Sia IG, DeBernardi MJ, Smith TF, Patel R, Jenkins G, Harmsen WS, Vanness DJ, Wiesner RH.
    J Infect Dis; 2002 Apr 01; 185(7):854-60. PubMed ID: 11920308
    [Abstract] [Full Text] [Related]

  • 20. Oral ganciclovir shows benefit for prevention of CMV disease in liver transplant recipients.
    J Int Assoc Physicians AIDS Care; 1996 Jul 01; 2(7):43-4. PubMed ID: 11363747
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.